GlobeNewswire·Nov 6, 2026, 9:00 AM ET

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

Analysis of paired biopsies from the Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ & CD8+/IDO+ ratios in tumor & stroma.
Findings provide an immunological mechanism for the 14.7-month improvement in median overall survival observed with IMNN-001 in OVATION 2.
The addition of IMNN-001 to standard-of-care neoadjuvant & adjuvant chemotherapy drove increased anti-tumoral T-cell activity, while chemotherapy supported proinflammatory macrophage polarization.
Results indicate IMNN-001 shifts the tumor microenvironment from immunologically "cold" to "hot," enhancing T-cell activation & persistence while suppressing pro-tumor myeloid cells.
IMNN-001 demonstrated a survival benefit of 14.7 months (45.1 months vs 30.4 months) & a three-month improvement in median progression-free survival compared to standard-of-care alone.
The pivotal Phase 3 OVATION 3 trial is currently enrolling to confirm safety & survival benefits in frontline advanced ovarian cancer.
Data supports IMUNON's TheraPlas platform & was presented at the SITC 41st Annual Meeting in Phoenix, Arizona, on November 7, 2026.
IMNN-001 functions as an IL-12 DNA plasmid delivered intraperitoneally to induce local immune responses with minimal systemic exposure.

Company: Imunon, Inc.
Keywords: Nasdaq:IMNN, Imunon, Inc., IMUNON, Inc., Nasdaq: IMNN, clinical-stage biotechnology, DNA-mediated immunotherapies, Phase 2 OVATION 2 study